Abcam, ab271907, Anti-Somatostatin Receptor 2 antibody [UMB1] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal Somatostatin Receptor 2 antibody. Carrier free. Suitable for IHC-P, IP, WB and reacts with Human samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:UMB1,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:WB, IP, IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab271907 is the carrier-free version of
ab134152
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The somatostatin receptor 2 (SSTR2) also known as SS2R serves as a G protein-coupled receptor with a molecular mass of approximately 40-60 kDa. SSTR2 specifically binds somatostatin a peptide hormone that regulates the endocrine system neurotransmission and cell proliferation via interaction with various somatostatin receptors. Scientists find SSTR2 expressed in high levels in the pituitary gland central nervous system gastrointestinal tract and pancreatic cells.
Biological function summary
Somatostatin receptor 2 mediates the inhibitory effects of somatostatin on cell growth and the release of other hormones. It functions as part of the receptor complex modulating intracellular signaling pathways. SSTR2 often interacts closely with other molecules like G proteins to inhibit adenylyl cyclase reducing cyclic AMP (cAMP) levels and influencing diverse cellular responses. The receptor's ability to influence such processes emphasizes its role in maintaining cellular and systemic homeostasis.
Pathways
Somatostatin receptor 2 plays an important role in the inhibitory signaling pathways related to growth hormone regulation and neurotransmitter release. SSTR2 actively participates in the somatostatin signaling pathway intimately interacting with proteins such as adenylate cyclase and phospholipase C. Another important pathway includes the regulation of the MAPK pathway serving to modulate cell proliferation and survival reiterating its regulatory function within endocrine signaling and cellular communication.
Somatostatin receptor 2 demonstrates significant involvement in neuroendocrine tumors and acromegaly. The overexpression of SSTR2 in neuroendocrine tumors provides a valuable target for diagnostic imaging and therapeutic interventions using somatostatin analogs. In acromegaly where excess growth hormone production occurs SSTR2's modulation of growth hormone release becomes important; it often works alongside growth hormone receptors and IGF-1 to limit abnormal growth. Therefore the receptor's targeting offers therapeutic potential and advances disease understanding.